THE ROLE OF STATINS IN REDUCING THE RISK OF NO-SLOW-REFLOW BY CORONARY REVASCULARISATION

DOI: https://doi.org/10.29296/25877305-2023-03-09
Issue: 
3
Year: 
2023

Associate Professor A. Khripunova(1), Candidate of Medical Sciences; G. Sazanov(2); I. Znamenskaya(1), Candidate of Medical Sciences; Associate Professor
I. Khripunova(1), Candidate of Medical Sciences
1-Stavropol State Medical University
2-Stavropol regional clinical hospital

Blood flow restoration by percutaneous coronary intervention (PCI) is currently one of the main approaches to the treatment of patients with acute myocardial infarction. However, suboptimal coronary reperfusion associated with microvascular obstruction (no-slow-reflow phenomenon) may occur in 30–60% of cases after PCI. This review presents an analysis of the effect of statin therapy on the risk of no-slow-reflow and clinical prognosis in patients after PCI.

Keywords: 
cardiology
acute myocardial infarction
no-slow-reflow phenomenon
percutaneous coronary intervention
statins
non-invasive mechanical ventilation
intensive care unit for newborns
respiratory distress syndrome in a newborn
extremely low body weight.



References: 
  1. Вышлов Е.В., Рябов В.В. Коронарная реперфузия при остром инфаркте миокарда. Томск: НИИ кардиологии, Томский НИМЦ, 2019; 196 с. [Vyshlov E.V., Ryabov V.V. Coronary reperfusion in acute myocardial infarction. Tomsk: Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 2019; 196 р. (in Russ.)].
  2. Writing Committee Members, Lawton JS, Tamis-Holland JE, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022; 79 (2): e21–e129. DOI: 10.1016/j.jacc.2021.09.006
  3. Ibanez B., James S., Agewall S. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018; 39: 119–77. DOI: 10.1093/eurheartj/ehx393
  4. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985; 312 (14): 932–6. DOI: 10.1056/NEJM198504043121437
  5. Niccoli G., Kharbanda R.K., Crea F. et al. No-reflow: Again prevention is better than treatment. Eur Heart J. 2010; 31 (20): 2449–55. DOI: 10.1093/eurheartj/ehq299
  6. Kaul S. The “no reflow” phenomenon following acute myocardial infarction: Mechanisms and treatment options. J Cardiol. 2014; 64 (2): 77–85. DOI: 10.1016/j.jjcc.2014.03.008
  7. Исхаков М.М., Тагирова Д.Р., Газизов Н.В. и др. Феномен «No-reflow»: клинические аспекты неудачи реперфузии. Казанский медицинский журнал. 2015; 96 (3): 391–6 [Iskhakov M.M., Tagirova D.R., Gazizov N.V. et al. «No-Reflow» Phenomenon: Clinical Aspects of Reperfusion Failure. Kazan Medical Journal. 2015; 96 (3): 391–6 (in Russ.)]. DOI: 10.17750/KMJ2015-391
  8. Tasar O., Karabay A.K., Oduncu V. et al. Predictors and outcomes of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. 2019; 30 (4): 270–6. DOI: 10.1097/MCA.0000000000000726
  9. Niccoli G., Burzotta F., Galiuto L. et al. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009; 54 (4): 281–92. DOI: 10.1016/j.jacc.2009.03.054
  10. De Waha S., Patel M.R., Granger C.B. et al. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: An individual patient data pooled analysis from seven randomized trials. Eur Heart J. 2017; 38 (47): 3502–10. DOI: 10.1093/eurheartj/ehx414
  11. Caiazzo G., Musci R.L., Frediani L. et al. State of the Art: No-Reflow Phenomenon. Cardiol Clin. 2020; 38 (4): 563–73. DOI: 10.1016/j.ccl.2020.07.001
  12. Kaur G., Baghdasaryan P., Natarajan B. et al. Pathophysiology, Diagnosis, and Management of Coronary No-Reflow Phenomenon. Int J Angiol. 2021; 30 (1): 15–21. DOI: 10.1055/s-0041-1725979
  13. Riksen N.P., Franke B., van den Broek P. et al. The 1976C>T polymorphism in the adenosine A2A receptor gene does not affect the vasodilator response to adenosine in humans in vivo. Pharmacogenet Genom. 2007; 17 (7): 551–4. DOI: 10.1097/FPC.0b013e32803fb78f
  14. Kloner R.A., King K.S., Harrington M.G. No-reflow phenomenon in the heart and brain. Am J Physiol Heart Circ Physiol. 2018; 315 (3): H550-H562. DOI: 10.1152/ajpheart.00183.2018
  15. Faruk Akturk I., Arif Yalcin A., Biyik I. et al. Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of noreflow phenomenon in patients with acute myocardial infarction. Minerva Cardioangiol. 2014; 62 (5): 389–97.
  16. Theilmeier G., Verhamme P., Dymarkowski M. et al. Hypercholesterolemia in minipigs impairs left ventricular response to stress: association with decreased coronary flow reserve and reduced capillary density. Circulation. 2002; 106 (9): 1140–6. DOI: 10.1161/01.cir.0000026805.41747.54
  17. Patti G., Pasceri V., Colonna G. et al. Atorvastatin pretreatment im-proves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007; 49 (12): 1272–8. DOI: 10.1016/j.jacc.2007.02.025
  18. Yun K.H., Jeong M.H., Oh S.K. et al. The beneficial effect: of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. 2009; 137 (3): 246–51. DOI: 10.1016/j.ijcard.2008.06.055
  19. Ishii H., Ichimiya S., Kanashiro M. et al. Effects of receipt of chronic statin therapy before the onset of acute myocardial infarction: a retrospective study in patients undergoing primary percutaneous coronary intervention. Clin Ther. 2006; 28 (11): 1812–9. DOI: 10.1016/j.clinthera.2006.11.003
  20. Chang S.M., Yazbek N., Lakkis N.M. Use of statins prior to percutane¬ous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv. 2004; 62 (2): 193–7. DOI: 10.1002/ccd.20078
  21. Yun K.H., Shin I.S., Shin S.N. et al. Effect of Previous Statin Therapy in Patients With Acute Coronary Syndrome and Percutaneous Coronary Intervention. Korean Circ J. 2011; 41 (8): 458–63. DOI: 10.4070/kcj.2011.41.8.458
  22. Briguori C., Colombo A., Airoldi F. et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J. 2004; 25 (20): 1822–8. DOI: 10.1016/j.ehj.2004.07.017
  23. Ebrahimi R., Saleh J., Toggart E. et al. Effect of preprocedural statin use on procedural myocardial infarction and major cardiac adverse events in percutaneous coronary intervention: a meta-analysis. J Invasive Cardiol. 2008; 20 (6): 292–5.
  24. Ray K.K., Cannon C.P., McCabe C.H. et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005; 46 (8): 1405–10. DOI: 10.1016/j.jacc.2005.03.077
  25. Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001; 285 (13): 1711–7. DOI: 10.1001/jama.285.13.1711
  26. Kim J.-S., Kim J., Choi D. et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: The STATIN STEMI trial. JACC Cardiovasc. Interv. 2010; 3 (3): 332–9. DOI: 10.1016/j.jcin.2009.11.021
  27. Spencer F.A., Allegrone J., Goldberg R.J. et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med. 2004; 140 (11): 857–66. DOI: 10.7326/0003-4819-140-11-200406010-00006
  28. Bauer T., Böhm M., Zahn R. et al. Effect of chronic statin pretreatment on hospital outcome in patients with acute non-ST-elevation myocardial infarction. J Cardiovasc Pharmacol. 2009; 53 (2): 132–6. DOI: 10.1097/FJC.0b013e3181976a3c
  29. Annibali G., Scrocca I., Aranzulla T.C. et al. «No-Reflow» Phenomenon: A Contemporary Review. J Clin Med. 2022; 11 (8): 2233. DOI: 10.3390/jcm11082233
  30. Alidoosti M., Lotfi R., Lotfi-Tokaldany M. et al. Correlates of the «No-Reflow» or «Slow-Flow» Phenomenon in Patients Undergoing Primary Percutaneous Coronary Intervention. J Tehran Heart Cent. 2018; 13 (3): 108–14.
  31. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001; 21 (11): 1712–9. DOI: 10.1161/hq1101.098486
  32. Sposito A.C., Chapman M.J. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol. 2002; 22 (10): 1524–34. DOI: 10.1161/01.atv.0000032033.39301.6a
  33. Kurita A., Takashima H., Ando H. et al. Effects of eicosapentaenoic acid on peri-procedural (type IVa) myocardial infarction following elective coronary stenting. J Cardiol. 2015; 66 (2): 114–9. DOI: 10.1016/j.jjcc.2014.09.004
  34. Prasad A., Herrmann J. Myocardial infarction due to percutaneous coronary intervention. N Engl J Med. 2011; 364 (5): 453–64. DOI: 10.1056/NEJMra091213
  35. Майер Р.Ф., Обладен М. Интенсивная терапия новорожденных. Доказательство и опыт. Пер. с нем. М.: МЕДпресс-информ, 2021; 768 с. [Maier R.F., Obladen M. Neugeborenen – intensivmedizin. Evidenz und Erfahrung. Transl. From German. M.: MEDpress-inform, 2021; 768 s. (in Russ.)].
  36. Заболевания нервной системы у детей: в 2-х т. Т.1. Под ред. Ж. Айкарди и др.; пер с англ.; общ. ред. А.А. Скоромца. М.: Издательство Панфилова, БИНОМ, Лаборатория знаний, 2013; 568 с. [Diseases of the nervous system in children: in 2 volumes. Vol. 1. Ed. J. Aikardi et al.; transl. from English; ed. A.A. Skoromets. M.: Panfilov Publishing House, BINOM, Laboratoriya znanii, 2013; 568 p. (in Russ.)].
  37. Евтушенко С.К., Скоромец А.А., Скоромец А.П. и др. Избранные лекции по общей и детской неврологии. М.: ООО «Медицинское информационное агентство», 2021; 840 с. [Evtushenko S.K., Skoromets A.A., Skoromets A.P. et al. Selected lectures on general and child neurology. M.: «Medical Information Agency», 2021; 840 p. (in Russ.)].
  38. Рабочая тетрадь по госпитальной педиатрии. Модуль «Неонатология»: учебно-методическое пособие. Под ред. П.В. Шумилова. М.: РНИМУ им. Н.И. Пирогова, 2019; 176 с. [Workbook on hospital pediatrics. Module «Neonatology»: teaching aid. Ed. P.V. Shumilova. M.: Pirogov Russian National Research Medical University, 2019; 176 p. (in Russ.)].
  39. Неотложная рентгенодиагностика в неонатологии и педиатрии (атлас рентгеновских изображений). Руководство для врачей. Под ред. Г.Е. Труфанова, Л.Г. Константиновой. СПб: ООО «Медиздат – СПб», 2020; 184 с. [Emergency X-ray diagnostics in neonatology and pediatrics (Atlas of X-ray images). Manual for physicians. Ed. G.E. Trufanova, L.G. Konstantinova. SPb: OOO «Medizdat – St. Peterburg», 2020; 184 p. (in Russ.)].
  40. Shovkun L.A., Aksenova V.A., Kudlai D.A. et al. The role of immunological tests in the diagnosis of tuberculosis infection in children with juvenile idiopathic arthritis (JIA). Eur Resp J Suppl. 2018; 52 (S62): PA2733